EVERSANA, a pharma commercialization firm, and Waltz Well being, a digital prescription drug firm, are merging right into a $6 billion entity, they introduced on Tuesday.
Chicago-based EVERSANA serves greater than 650 pharmaceutical and biotech corporations and helps them convey therapies to market. Its providers embody the distribution of stock and advertising and marketing and promoting to physicians. It additionally helped Eli Lilly with the creation of LillyDirect, a direct-to-consumer platform that permits sufferers to entry sure Eli Lilly drugs, together with the GLP-1 Zepbound.
Waltz Well being, additionally based mostly in Chicago, serves payers, employers and pharmacies. It has a platform known as Waltz Join, which matches sufferers to essentially the most appropriate pharmacy for them after they’re prescribed a specialty remedy. It additionally gives well being plans details about the member’s situation, prescription, the pharmacy’s contact info and extra.
The merger will convey collectively these corporations’ capabilities beneath the EVERSANA title. The phrases of the deal weren’t disclosed.
The mixed firm will proceed promoting Waltz Join and constructing out its pharmacy community. EVERSANA, in the meantime, will create a brand new mannequin that straight connects pharmaceutical corporations to payers and sufferers, much like LillyDirect. It would take that mannequin to payers and put it into funded profit plans.
The businesses intention to deal with the excessive value of pharmaceuticals via the merger, significantly specialty medicine like GLP-1s and oncology therapies. These include extraordinarily excessive listing costs and sometimes have massive rebates hooked up to them, mentioned Mark Thierer, co-founder and CEO of Waltz Well being.
“Our mannequin is definitely bridging payers with the pharmaceutical business, and our hope is to create a enterprise mannequin with much less abrasion, much less pace bumps to get these therapies into sufferers’ fingers,” Thierer mentioned. “We’re creating a greater member expertise. … We’re operating alongside the present mannequin. We’re not seeking to blow it up or in any manner disintermediate it.”
Thierer will function CEO of the mixed firm. Previous to Waltz Well being, he was the CEO of OptumRx following UnitedHealth Group’s $13 billion acquisition of Catamaran.
EVERSANA’s former CEO, Jim Lang, might be a board member.
Thierer has additionally been the chairman of EVERSANA for the final eight years, which gave him a “entrance row seat” within the firm.
“The notion of attempting to bridge pharmaceutical corporations with payers is one thing that nobody had finished, and it had been occurring to me over time that this could possibly be match. … We began working collectively a very long time in the past on single, standalone initiatives, and as we progressed, it grew to become clearer and clearer that there was a hand-in-glove match between these organizations and a giant alternative for a technique play, a primary mover to bridge pharma with payers at scale,” he mentioned.
Photograph: Stas_V, Getty Pictures
